NVS - Novartis AG

NYSE - NYSE Delayed price. Currency in USD
77.06
-0.09 (-0.12%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous close77.15
Open77.38
Bid75.80 x 3100
Ask78.64 x 1300
Day's range76.91 - 77.43
52-week range75.73 - 94.19
Volume1,478,946
Avg. volume1,706,180
Market cap179.633B
Beta0.89
PE ratio (TTM)23.71
EPS (TTM)3.25
Earnings dateN/A
Forward dividend & yield2.98 (3.80%)
Ex-dividend date2018-03-06
1y target est88.16
Trade prices are not sourced from all markets
  • Novartis General Counsel Out Over Cohen Contract
    Bloomberg Video5 days ago

    Novartis General Counsel Out Over Cohen Contract

    May.16 -- Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's Drew Armstrong reports on "Bloomberg Markets: Balance of Power."

  • Investors have shrugged off Trump drug price plan, but it is still early days
    CNBC2 hours ago

    Investors have shrugged off Trump drug price plan, but it is still early days

    Biotech companies and pharmacy benefit managers defied the overall market trend, despite more noise about President Trump's drug plan.

  • Cohen lawyers object to Stormy Daniels' attorney Michael Avenatti intervening in New York case
    CNBC3 days ago

    Cohen lawyers object to Stormy Daniels' attorney Michael Avenatti intervening in New York case

    Cohen is under federal criminal investigation for, among other things, a $130,000 payment to the porn star Stormy Daniels in exchange for her silence about an alleged affair with President Trump in 2006.

  • Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst
    CNBC3 days ago

    Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

    Aimovig from Amgen and Novartis could become a $1 billion to $2 billion business in five years, say one Wall Street analyst.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks3 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • The Wall Street Journal3 days ago

    New Migraine Drugs Offer Hope to Sufferers

    The FDA has approved a new drug called Aimovig that is touted as the first treatment designed specifically to prevent migraines.

  • MarketWatch3 days ago

    ‘Holy of holies’ — Inside the financial crime database that sprung a leak

    A blockbuster story about the whistleblower who revealed President Donald Trump’s personal lawyer received payments from various companies has placed attention on a fairly obscure unit with the Treasury Department that’s at the heart of regulating the financial system. The New Yorker’s Ronan Farrow interviewed someone he called a “law-enforcement official” who leaked, per the report, after not being able to find two suspicious-activity reports on Michael Cohen, who received big payments from AT&T, Novartis and Korea Aerospace Industries.

  • Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
    Zacks3 days ago

    Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

    Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

  • Label Expansion May Boost Cabometyx’s Revenue in 2018
    Market Realist3 days ago

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist3 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist3 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • MarketWatch3 days ago

    FDA approves anti-migraine drug from Novartis, Amgen

    Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.

  • US approves 1st drug developed to prevent chronic migraines
    Associated Press4 days ago

    US approves 1st drug developed to prevent chronic migraines

    TRENTON, N.J. (AP) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines.

  • FDA names drugmakers accused of blocking cheaper generics
    Associated Press4 days ago

    FDA names drugmakers accused of blocking cheaper generics

    TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.

  • Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
    Market Realist4 days ago

    Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

    Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.

  • The Wall Street Journal4 days ago

    [$$] Novartis Top Lawyer Departs Over Cohen Payments

    ZURICH——A top executive at Swiss drugmaker Novartis AG is stepping down amid the controversy over payments that corporations made to a company owned by U.S. President Donald Trump’s longtime personal lawyer . Novartis said Wednesday that general counsel Felix Ehrat, 61 years old, is retiring from the company in connection with $1.2 million in payments it made over the course of a year to Michael Cohen’s shell company, Essential Consultants LLC. It was the second high-profile departure in less than a week in relation to payments to the company.

  • Novartis Gains Ground, Completes the AveXis Acquisition
    Market Realist4 days ago

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.

  • Missing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report
    CNBC4 days ago

    Missing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report

    A law enforcement official leaked a suspicious activity report about Trump lawyer Michael Cohen and payments by Novartis and AT&T to his Essential Consultants company, The New Yorker reports.

  • The Wall Street Journal4 days ago

    [$$] The Novartis-Cohen Connection Explained

    Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it has drawn the attention of prosecutors at home. Novartis is a Basel-based multinational pharmaceutical company that makes a number of drugs, including treatments for cancer, heart conditions, and autoimmune diseases.

  • Novartis General Counsel Out Over Cohen Contract
    Bloomberg5 days ago

    Novartis General Counsel Out Over Cohen Contract

    Novartis AG’s top lawyer, Felix Ehrat, became the first executive to take the fall for the controversial $1.2 million in payments he helped arrange to President Donald Trump’s attorney Michael Cohen. Bloomberg's ...

  • MarketWatch5 days ago

    Here’s how Novartis’s former CEO explained hiring Michael Cohen

    Joseph Jimenez, the former chief executive of Novartis, has an explanation for why the Swiss pharmaceutical lavished President Donald Trump’s personal lawyer Michael Cohen with a $1.2 million consulting contract. The hiring of Cohen by Novartis (NVS) , AT&T Inc. (XNYS:T) and Korea Aerospace Industries — revealed by the lawyer of the adult-film star who has alleged having an affair with Trump — has set off a firestorm in Washington and opened up the companies to potential legal liability.

  • How Trump's Fix-It Man Became a $1.2 Million Headache for Novartis
    Bloomberg5 days ago

    How Trump's Fix-It Man Became a $1.2 Million Headache for Novartis

    When Michael Cohen showed up at Novartis AG last year proposing to help the drugmaker navigate the Donald Trump administration, it sounded like a promising opportunity. Cohen had, after all, served as an attorney for Trump and had close ties to the new president. It didn’t take long for Novartis to conclude Cohen was full of hot air.

  • Novartis top lawyer exits over Trump attorney deal 'mistake'
    Reuters5 days ago

    Novartis top lawyer exits over Trump attorney deal 'mistake'

    Novartis's top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behaviour.

  • Novartis top lawyer exits over Trump attorney deal 'mistake'
    Reuters5 days ago

    Novartis top lawyer exits over Trump attorney deal 'mistake'

    Novartis's (NOVN.S) top lawyer quit on Wednesday over a $1.2 million contract he co-signed with U.S. President Donald Trump's personal attorney, a deal the Swiss drugmaker's ex-CEO also said was a mistake. The contract with Michael Cohen's Essential Consultants, the same firm used to pay porn star Stormy Daniels, has distracted Novartis's efforts to improve its image after a series of missteps. Current CEO Vas Narasimhan also said the contract was a major mistake at a meeting with investors in Basel on Wednesday and said Novartis was developing a principles-, not rules-based system to help avert corruption and guide employees' behavior.

  • Dow seesaws, hedge funds make surprising tech giant trades
    Yahoo Finance5 days ago

    Dow seesaws, hedge funds make surprising tech giant trades

    Yahoo Finance's LIVE market coverage and analysis of stocks and bonds begins each day at 11:45 a.m. ET.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes